LncRNA UBE2R2-AS1, as prognostic marker, promotes cell proliferation and EMT in prostate cancer
- PMID: 35916204
- DOI: 10.14670/HH-18-505
LncRNA UBE2R2-AS1, as prognostic marker, promotes cell proliferation and EMT in prostate cancer
Abstract
Background: Long noncoding RNA ubiquitin-conjugating enzyme E2 R2 antisense RNA 1 (UBE2R2-AS1) has been recently reported to participate in the progression of tumors, including glioma and liver cancer. However, the roles of UBE2R2-AS1 in prostate cancer (PC) remained poorly understood.
Methods: The expression of UBE2R2-AS1 was determined in tumor tissues and paired adjacent tissues from PC patients using quantitative reverse transcription PCR analysis. Correlation between UBE2R2-AS1 expression and clinicopathological parameters and overall survival were investigated by Chi-square test and Kaplan-Meier method analysis. The in vitro experiments, including CCK-8 assay, colony formation, flow cytometry and transwell assay were performed to investigate the functional role of UBE2R2-AS1 knockdown or overexpression on PC cell lines (PC-3 and DU145). Related protein expression levels were measured by western blot analysis.
Results: Our data showed that UBE2R2-AS1 expression was significantly upregulated in PC tissues compared with that in adjacent tissues. The high levels of UBE2R2-AS1 were associated with high Gleason score, advanced clinical T stage, lymph node metastasis and poor prognosis. Knockdown of UBE2R2-AS1 suppressed cell proliferation, migration and invasion, induced cell cycle G0/G1 arrest and apoptosis in PC cells, along with decreased expression of PCNA, CDK4, Cyclin D1, Bcl-2, N-cadherin and Vimentin, and increased E-cadherin expression. Overexpression of UBE12R2-AS1 obtained the opposite results in PC cells.
Conclusions: Our findings suggest that UBE2R2-AS1 might be a potential diagnostic and/or therapeutic target in PC.
©The Author(s) 2023. Open Access. This article is licensed under a Creative Commons CC-BY International License.
Similar articles
-
UBE2R2-AS1, as a prognostic marker of gastric cancer, promotes the malignant phenotype of gastric cancer cells.Histol Histopathol. 2024 Jun;39(6):739-745. doi: 10.14670/HH-18-677. Epub 2023 Nov 21. Histol Histopathol. 2024. PMID: 38009743
-
NUBE2R2-AS1 as Prognostic Marker, Promotes Cell Migration and Invasion in Non-Small Cell Lung Cancer by Modulating Epithelial-Mesenchymal Transition Process.Ann Clin Lab Sci. 2022 May;52(3):462-469. Ann Clin Lab Sci. 2022. PMID: 35777800
-
LncRNA SSTR5-AS1 as a Prognostic Marker Promotes Cell Proliferation and Epithelial-to-Mesenchymal Transition in Prostate Cancer.Crit Rev Eukaryot Gene Expr. 2023;33(2):1-12. doi: 10.1615/CritRevEukaryotGeneExpr.2022042183. Crit Rev Eukaryot Gene Expr. 2023. PMID: 36734853
-
Long noncoding RNA ABHD11-AS1 predicts the prognosis of pancreatic cancer patients and serves as a promoter by activating the PI3K-AKT pathway.Eur Rev Med Pharmacol Sci. 2018 Dec;22(24):8630-8639. doi: 10.26355/eurrev_201812_16627. Eur Rev Med Pharmacol Sci. 2018. PMID: 30575903
-
UBE2R2-AS1 Inhibits Xenograft Growth in Nude Mice and Correlates with a Positive Prognosis in Glioma.J Mol Neurosci. 2021 Aug;71(8):1605-1613. doi: 10.1007/s12031-021-01793-y. Epub 2021 Feb 2. J Mol Neurosci. 2021. PMID: 33528791
Cited by
-
UBE2R2-AS1, as a prognostic marker of gastric cancer, promotes the malignant phenotype of gastric cancer cells.Histol Histopathol. 2024 Jun;39(6):739-745. doi: 10.14670/HH-18-677. Epub 2023 Nov 21. Histol Histopathol. 2024. PMID: 38009743
-
Long non-coding RNA AC245100.4 activates the PI3K/AKT pathway to promote PCa cell proliferation by elevating PAR2.Heliyon. 2023 Jun 3;9(6):e16870. doi: 10.1016/j.heliyon.2023.e16870. eCollection 2023 Jun. Heliyon. 2023. PMID: 37346322 Free PMC article.
-
Emerging roles and clinical perspectives of long noncoding RNAs in prostate cancer.Med Oncol. 2025 Jun 27;42(8):289. doi: 10.1007/s12032-025-02859-2. Med Oncol. 2025. PMID: 40576878 Review.
-
Targeting IL-8 and Its Receptors in Prostate Cancer: Inflammation, Stress Response, and Treatment Resistance.Cancers (Basel). 2024 Aug 8;16(16):2797. doi: 10.3390/cancers16162797. Cancers (Basel). 2024. PMID: 39199570 Free PMC article. Review.
References
-
- Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A. and Jemal A. (2018). Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394-424. - PubMed
-
- Crehange G., Izaguirre A., Weinberg V., Hsu C.C., Gottschalk A.R., Hsu I.C., Shinohara K., Carroll P. and Roach M. 3rd (2016). Long-term outcomes following radiation therapy for prostate cancer patients with lymph node metastases at diagnosis treated with and without surgery. Am. J. Clin. Oncol. Cancer 39, 167-172. - PubMed
-
- de Oliveira J.C., Oliveira L.C., Mathias C., Pedroso G.A., Lemos D.S., Salviano-Silva A., Jucoski T.S., Lobo-Alves S.C., Zambalde E.P., Cipolla G.A. and Gradia D.F. (2019). Long non-coding RNAs in cancer: Another layer of complexity. J. Gene. Med. 21, e3065. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous